Published in Trends Immunol on March 23, 2012
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. Cell (2015) 2.60
Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol (2013) 1.70
Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression. Immunity (2014) 1.69
A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells. Cell (2016) 1.61
Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res (2014) 1.52
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood (2013) 1.44
Radiation and immunotherapy: a synergistic combination. J Clin Invest (2013) 1.44
Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than "Exhaustion" of Human CD8 T Cells. Front Immunol (2013) 1.34
T-cell exhaustion in the tumor microenvironment. Cell Death Dis (2015) 1.32
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Front Immunol (2015) 1.12
Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ. Cancer Res (2014) 1.10
Inhibitory Receptors Beyond T Cell Exhaustion. Front Immunol (2015) 1.05
Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients. Eur J Immunol (2012) 1.01
What makes a blood cell based miRNA expression pattern disease specific?--a miRNome analysis of blood cell subsets in lung cancer patients and healthy controls. Oncotarget (2014) 0.99
Beneficial and Detrimental Roles of NLRs in Carcinogenesis. Front Immunol (2013) 0.94
Human melanoma-specific CD8(+) T-cells from metastases are capable of antigen-specific degranulation and cytolysis directly ex vivo. Oncoimmunology (2012) 0.92
Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models. Front Immunol (2015) 0.91
MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines. Ther Adv Vaccines (2014) 0.91
Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8(+) T-cell responses to anticancer vaccines. Oncoimmunology (2013) 0.88
Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. J Immunother Cancer (2015) 0.88
Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy. Clin Cancer Res (2013) 0.88
Biomaterials and emerging anticancer therapeutics: engineering the microenvironment. Nat Rev Cancer (2015) 0.88
Anti-tumor immunity: myeloid leukocytes control the immune landscape. Cell Immunol (2012) 0.84
Targeting Transcriptional Regulators of CD8+ T Cell Dysfunction to Boost Anti-Tumor Immunity. Vaccines (Basel) (2015) 0.81
Metabolic communication in tumors: a new layer of immunoregulation for immune evasion. J Immunother Cancer (2016) 0.81
Regulatory circuits of T cell function in cancer. Nat Rev Immunol (2016) 0.81
Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model. J Immunol (2016) 0.80
Neem leaf glycoprotein activates CD8(+) T cells to promote therapeutic anti-tumor immunity inhibiting the growth of mouse sarcoma. PLoS One (2013) 0.80
A mathematical model of immune activation with a unified self-nonself concept. Front Immunol (2013) 0.80
Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization. Cancer Immunol Res (2016) 0.79
Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model. Br J Haematol (2015) 0.79
Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response. J Immunol Res (2016) 0.78
Adoptive T-cell therapy for Leukemia. Mol Cell Ther (2014) 0.77
Molecular insights for optimizing T cell receptor specificity against cancer. Front Immunol (2013) 0.77
Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. Oncoimmunology (2015) 0.77
Naïve CD8(+) T cell derived tumor-specific cytotoxic effectors as a potential remedy for overcoming TGF-β immunosuppression in the tumor microenvironment. Sci Rep (2016) 0.76
Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients. Clin Dev Immunol (2013) 0.76
Reenergizing T cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries. Curr Opin Immunol (2017) 0.76
Cerebral Gluconeogenesis and Diseases. Front Pharmacol (2017) 0.75
Tolerance of Tumor-Specific T cells in Melanoma Metastases. J Clin Cell Immunol (2016) 0.75
Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer. Hum Vaccin Immunother (2014) 0.75
Increased HIF-1alpha expression in tumor cells and lymphocytes of tumor microenvironments predicts unfavorable survival in esophageal squamous cell carcinoma patients. Int J Clin Exp Pathol (2014) 0.75
The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort. Oncotarget (2017) 0.75
Absence of Grail promotes CD8(+) T cell anti-tumour activity. Nat Commun (2017) 0.75
Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. J Clin Invest (2011) 3.28
Four functionally distinct populations of human effector-memory CD8+ T lymphocytes. J Immunol (2007) 2.59
Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One (2012) 1.77
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol (2006) 1.74
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest (2009) 1.71
Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol (2002) 1.68
Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev (2002) 1.58
T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat Immunol (2013) 1.57
Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med (2002) 1.48
RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood (2007) 1.47
Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med (2002) 1.44
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother (2013) 1.42
Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol (2010) 1.33
Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples. J Immunol Methods (2005) 1.33
The epidemiology of pertussis in Germany: past and present. BMC Infect Dis (2009) 1.31
Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun (2004) 1.29
Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. J Immunol (2009) 1.25
Dextramers: new generation of fluorescent MHC class I/peptide multimers for visualization of antigen-specific CD8+ T cells. J Immunol Methods (2006) 1.13
Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens. Cancer Res (2006) 1.11
Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients. J Immunol (2009) 1.09
Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol Immunother (2003) 1.09
Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol (2012) 1.06
The human T cell response to melanoma antigens. Adv Immunol (2006) 1.05
Influenza vaccination in German health care workers: effects and findings after two rounds of a nationwide awareness campaign. Vaccine (2006) 1.04
Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients. Eur J Immunol (2012) 1.01
Clonotype selection and composition of human CD8 T cells specific for persistent herpes viruses varies with differentiation but is stable over time. J Immunol (2009) 1.01
Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. Int J Cancer (2010) 1.01
The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin Ther Targets (2011) 1.00
Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immun (2003) 1.00
SHP-1 phosphatase activity counteracts increased T cell receptor affinity. J Clin Invest (2013) 1.00
Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. Clin Cancer Res (2003) 1.00
Efficient T cell repertoire selection in tetraparental chimeric mice independent of thymic epithelial MHC. Proc Natl Acad Sci U S A (2003) 0.99
Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. J Immunol (2005) 0.99
Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells. Int J Cancer (2011) 0.99
Dominant human CD8 T cell clonotypes persist simultaneously as memory and effector cells in memory phase. J Immunol (2009) 0.98
In Vivo Persistence of Codominant Human CD8+ T Cell Clonotypes Is Not Limited by Replicative Senescence or Functional Alteration. J Immunol (2007) 0.97
Cases of rabies in Germany following organ transplantation. Euro Surveill (2005) 0.96
Assessing ageing of individual T lymphocytes: mission impossible? Mech Ageing Dev (2007) 0.95
Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues. Proc Natl Acad Sci U S A (2008) 0.94
Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J Immunol (2006) 0.94
Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles. Eur J Immunol (2005) 0.94
Progress and controversies in developing cancer vaccines. J Transl Med (2005) 0.93
Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts. Cancer Res (2009) 0.93
Human melanoma-specific CD8(+) T-cells from metastases are capable of antigen-specific degranulation and cytolysis directly ex vivo. Oncoimmunology (2012) 0.92
The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy. Curr Opin Pharmacol (2012) 0.92
A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide. J Immunol (2007) 0.92
Progress toward measles elimination in Germany. J Infect Dis (2003) 0.91
IL-12 controls cytotoxicity of a novel subset of self-antigen-specific human CD28+ cytolytic T cells. J Immunol (2007) 0.90
DiC14-amidine cationic liposomes stimulate myeloid dendritic cells through Toll-like receptor 4. Eur J Immunol (2008) 0.89
Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood. Cancer Immunol Immunother (2008) 0.89
Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer. Cancer Immunol Immunother (2006) 0.89
Unmet health care needs and impact on families with children with disabilities in Germany. Ambul Pediatr (2003) 0.88
Prognostic value of arginase-II expression and regulatory T-cell infiltration in head and neck squamous cell carcinoma. Int J Cancer (2012) 0.88
Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma. J Immunother (2007) 0.88
The anticonvulsant retigabine is a subtype selective modulator of GABAA receptors. Epilepsia (2015) 0.85
Virus-like particles induce robust human T-helper cell responses. Eur J Immunol (2011) 0.85
Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific cytotoxic T lymphocytes after vaccination with low peptide dose. Cancer Immunol Immunother (2011) 0.84
A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours. Eur J Cancer (2012) 0.84
Deciphering the unusual HLA-A2/Melan-A/MART-1-specific TCR repertoire in humans. Eur J Immunol (2014) 0.84
Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients. J Immunother (2010) 0.84
Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients. Cancer Immunol Immunother (2007) 0.83
Ex vivo characterization of allo-MHC-restricted T cells specific for a single MHC-peptide complex. J Immunol (2006) 0.82
Human thymus exports naive CD8 T cells that can home to nonlymphoid tissues. J Immunol (2004) 0.82
Novel soluble HLA-A2/MELAN-A complexes selectively stain a differentiation defective subpopulation of CD8+ T cells in patients with melanoma. Int J Cancer (2010) 0.81
T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. J Transl Med (2013) 0.81
Tissue homing and persistence of defined antigen-specific CD8+ tumor-reactive T-cell clones in long-term melanoma survivors. J Invest Dermatol (2006) 0.81
Serological analysis of human renal cell carcinoma. Int J Cancer (2006) 0.81
Identification of tumor-associated antigens by large-scale analysis of genes expressed in human colorectal cancer. Cancer Immun (2008) 0.81
Simultaneous coexpression of memory-related and effector-related genes by individual human CD8 T cells depends on antigen specificity and differentiation. J Immunother (2012) 0.80
A stepwise protocol to coat aAPC beads prevents out-competition of anti-CD3 mAb and consequent experimental artefacts. J Immunol Methods (2012) 0.80
MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. J Transl Med (2014) 0.80
Immunological techniques: ex vivo characterization of T cell-mediated immune responses in cancer. Curr Opin Immunol (2005) 0.80
Profile of a serial killer: cellular and molecular approaches to study individual cytotoxic T-cells following therapeutic vaccination. J Biomed Biotechnol (2010) 0.79
Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide. Eur J Immunol (2006) 0.79
Mobilizing and evaluating anticancer T cells: pitfalls and solutions. Expert Rev Vaccines (2013) 0.78
CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses. Cancer Immunol Immunother (2012) 0.78
Prediction of cross-recognition of peptide-HLA A2 by Melan-A-specific cytotoxic T lymphocytes using three-dimensional quantitative structure-activity relationships. PLoS One (2013) 0.78
Quantitative multiparameter assays to measure the effect of adjuvants on human antigen-specific CD8 T-cell responses. Methods Mol Biol (2010) 0.78
Therapeutic cancer vaccines based on molecularly defined human tumor antigens. Vaccine (2002) 0.78
Clinical Implications of CD8+ T-cell infiltration in frequent and rare cancers. J Invest Dermatol (2013) 0.77
Molecular insights for optimizing T cell receptor specificity against cancer. Front Immunol (2013) 0.77
CpG-ODN-induced sustained expression of BTLA mediating selective inhibition of human B cells. J Mol Med (Berl) (2012) 0.77
An unusual case of metastatic melanoma sensitive to chemotherapy and immunotherapy, with late immune escape in the brain. Cancer Immun (2008) 0.77
Persistence of EBV antigen-specific CD8 T cell clonotypes during homeostatic immune reconstitution in cancer patients. PLoS One (2013) 0.76
Free diC14-amidine liposomes inhibit the TNF-alpha secretion induced by CpG sequences and lipopolysaccharides: role of lipoproteins. Mol Membr Biol (2006) 0.75
Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant. J Immunother (2009) 0.75
Endotoxin and asthma. N Engl J Med (2003) 0.75
Tumor cell recognition efficiency by T cells. PLoS Med (2005) 0.75
Impact of orthologous melan-A peptide immunizations on the anti-self melan-A/HLA-A2 T cell cross-reactivity. J Immunol (2006) 0.75
Conference scene: Immune signatures in the tumor and beyond. Immunotherapy (2012) 0.75
Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy? J Immunother (2016) 0.75